VENUSREM Stock Overview
Engages in the pharmaceutical business in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Venus Remedies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹312.75 |
| 52 Week High | ₹430.00 |
| 52 Week Low | ₹281.10 |
| Beta | 1.14 |
| 1 Month Change | 4.72% |
| 3 Month Change | -8.58% |
| 1 Year Change | -19.80% |
| 3 Year Change | -16.68% |
| 5 Year Change | 1,271.71% |
| Change since IPO | -19.33% |
Recent News & Updates
Recent updates
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why
Sep 17
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%
Jun 14Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt
Jun 13Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%
Mar 14Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Oct 31Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly
Jun 03Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Jul 15Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
May 31I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease
Mar 30Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge
Feb 24Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
Feb 01Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching
Nov 16Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?
Mar 11We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt
Jan 14Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Is Venus Remedies (NSE:VENUSREM) A Risky Investment?
Sep 22Shareholder Returns
| VENUSREM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.2% | 0.8% | -4.2% |
| 1Y | -19.8% | 39.7% | 19.1% |
Return vs Industry: VENUSREM underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: VENUSREM underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility
| VENUSREM volatility | |
|---|---|
| VENUSREM Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: VENUSREM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: VENUSREM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,187 | Ashutosh Jain | www.venusremedies.com |
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones, immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, solvent, respiratory, and anticoagulant. It is also involved in the provision of portfolio of herbal products.
Venus Remedies Limited Fundamentals Summary
| VENUSREM fundamental statistics | |
|---|---|
| Market cap | ₹4.19b |
| Earnings (TTM) | ₹221.11m |
| Revenue (TTM) | ₹6.15b |
18.9x
P/E Ratio0.7x
P/S RatioIs VENUSREM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VENUSREM income statement (TTM) | |
|---|---|
| Revenue | ₹6.15b |
| Cost of Revenue | ₹3.76b |
| Gross Profit | ₹2.38b |
| Other Expenses | ₹2.16b |
| Earnings | ₹221.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 16.54 |
| Gross Margin | 38.79% |
| Net Profit Margin | 3.60% |
| Debt/Equity Ratio | 8.3% |
How did VENUSREM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashish Kushwaha | FirstCall Research |
| Nagaraju Airruva | FirstCall Research |